July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Single photodynamic therapy session for exudative circumscribed choroidal hemangiomas. Clinical series of 33 patients.
Author Affiliations & Notes
  • xavier proumen
    Ocular Oncology Unit, Institut Roi Albert 2, CUSL, Brussels, Belgium
  • Ann-Pascale guagnini
    Retina Unit, Institut Roi Albert 2, CUSL, Brussels, Belgium
  • Paulina Bartoszek
    Ocular Oncology Unit, Institut Roi Albert 2, CUSL, Brussels, Belgium
  • Alexandra Kozyreff
    Retina Unit, Institut Roi Albert 2, CUSL, Brussels, Belgium
  • Patrick De Potter
    Ocular Oncology Unit, Institut Roi Albert 2, CUSL, Brussels, Belgium
  • Footnotes
    Commercial Relationships   xavier proumen, None; Ann-Pascale guagnini, None; Paulina Bartoszek, None; Alexandra Kozyreff, None; Patrick De Potter, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5591. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      xavier proumen, Ann-Pascale guagnini, Paulina Bartoszek, Alexandra Kozyreff, Patrick De Potter; Single photodynamic therapy session for exudative circumscribed choroidal hemangiomas. Clinical series of 33 patients.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5591.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effectiveness of a single session of PDT for exudative circumscribed choroidal hemangiomas (CCH).

Methods : Prospective non comparative case series including 33 patients with symptomatic exudative CCH. Our protocol included a single session of PDT performed 2 minutes after IV bolus injection of verteporfin (6mg/m2) at 689nm with a light dose of 100J/cm2 (600mW/cm2 for 166 seconds).

Results : The mean tumor thickness before PDT was 3,5 mm (range, 2.6-6 mm) and the mean largest TBD was 6.6 mm (range, 4,5-12mm). After a mean follow-up of 104 months (range, 12-170 months), all CCH (100%) showed regressed tumor thickness, resolution of subretinal fluid and no recurrent leakage. Visual improvement was documented in 25 eyes (76%,P<0.001) and a flat tumor scar in 25 eyes ( 76%, P<0.001). No other PDT session was needed.

Conclusions : This protocol with a single session of PDT offered a safe and effective option in treating symptomatic exudative CCH in terms of visual recovery, tumor thickness regression, and resolution of subretinal fluid with exudative recurrence.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×